ADLIN Science × Eurofins Genomics: From Sample to Interpretation

ADLIN Science and Eurofins Genomics are partnering to facilitate and accelerate the use of genomic data

‍

Ebersberg, Germany, June 2, 2026 – Genomic data is growing faster than most teams can handle. Eurofins Genomics and ADLIN Science have joined forces to deliver an integrated, reproducible solution covering every step from biological sample to actionable insight.

‍

One goal: Making genomic data truly actionable

By combining their complementary expertise, the two companies offer their clients a unique and consistent workflow that covers the entire value chain—from data generation to interpretation—while addressing key challenges such as reproducibility and interoperability:

- Eurofins Genomics, a leading genomics provider, manages the entire data production process—from sample handling to sequencing—by leveraging its industrial-scale capabilities.

- ADLIN Science provides integrated software solutions to analyze, organize, and maximize the value of this data, particularly by integrating multiple data types (multi-omics) and offering advanced exploration tools.

‍

“This partnership between two European companies is built on a strong conviction: the value of genomics lies not only in data generation, but in the ability to organize, analyze, and interpret it within its scientific context. By combining our expertise with that of Eurofins Genomics, we offer an integrated approach that enables a seamless and reproducible process from sample to interpretation, across Europe.”

Paul Rinaudo, CEO of ADLIN Science

For Eurofins Genomics, this partnership represents a strategic step toward delivering end-to-end genomic solutions to its clients. By integrating ADLIN Science’s data structuring and analysis capabilities into its sequencing workflow, Eurofins Genomics strengthens its ability to support research and industrial teams throughout the entire data lifecycle—from sample to actionable insight.

‍

Accelerating applications in research and industry

The joint offering addresses a wide range of use cases in both research and industry, with an initial focus on the pharmaceutical sector and clinical studies, including:

• biomarker identification and validation,

• translational research and

• clinical programs,

• multi-omics data analysis,

• bioproduction and

• genetic stability monitoring,

• as well as applications in dermo-cosmetics and life sciences.

‍

In particular, it enables faster access to actionable results, improved reproducibility of analyses, better organization of data flows from sequencing to interpretation, and greater autonomy for scientific teams. These benefits are consistent with a fully integrated value chain approach.

‍

A structured and evolving collaboration

The partnership is based on a structured framework that includes joint marketing initiatives, coordinated business development efforts, and close technical collaboration to ensure system interoperability.

‍

‍

‍